Entero Therapeutics Inc. (ENTO) Advances GI Drug PipelineEntero Therapeutics Inc.BATS:ENTOtraderspro_chartsEntero Therapeutics Inc. (ENTO) is a clinical-stage biopharmaceutical company developing novel therapies for gastrointestinal (GI) disorders and inflammatory diseases. Using targeted drug delivery technology, Entero aims to treat conditions such as ulcerative colitis and Crohn’s disease with improved safety and efficacy. The company’s growth is fueled by the urgent need for better GI treatments, progress in its clinical programs, and innovation in precision drug delivery. On the chart, a confirmation bar with rising volume highlights bullish strength. The price has entered the momentum zone after breaking above the .236 Fibonacci level. A trailing stop can be placed just below this Fibonacci line using the Fibonacci snap tool, helping traders lock in gains while leaving room for more upside potential.